Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery

Documenti analoghi

• Why insulin aspart and insulin degludec exhibit distinct release mechanisms
  di: Zhuo Lin Li, et al.
  Pubblicazione: (2024)
• Sensor‐derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster acting insulin aspart or insulin aspart—A secondary analysis of the CopenFast trial
  di: Julie C. Søholm, et al.
  Pubblicazione: (2024)
• Faster‐acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non‐automated insulin pump and continuous glucose monitoring—A double‐blind randomized controlled crossover trial
  di: Ajenthen G. Ranjan, et al.
  Pubblicazione: (2025)
• Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study
  di: Leili Gao, et al.
  Pubblicazione: (2025)
• Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?
  di: Kowalczyk‐Korcz Emilia, et al.
  Pubblicazione: (2026)